Compare · AMLX vs NVO
AMLX vs NVO
Side-by-side comparison of Amylyx Pharmaceuticals Inc. (AMLX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMLX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 50.1x AMLX ($3.47B).
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 24 for AMLX).
- Company
- Amylyx Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.47B
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 4
- 4
- Recent ratings
- 24
- 25
Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AMLX
- SEC Form 4 filed by Amylyx Pharmaceuticals Inc.
- Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
- SEC Form 144 filed by Amylyx Pharmaceuticals Inc.
- Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
- Co-Chief Executive Officer Klee Justin B. sold $980,263 worth of shares (30,464 units at $32.18), decreasing direct ownership by 0.84% to 3,613,056 units (SEC Form 4) (for tax liability)
- Co-Chief Executive Officer Cohen Joshua B sold $980,504 worth of shares (30,464 units at $32.19), decreasing direct ownership by 0.84% to 3,613,123 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Mazzariello Gina sold $309,506 worth of shares (9,536 units at $32.46), decreasing direct ownership by 5% to 190,838 units (SEC Form 4) to cover taxes
- Chief Financial Officer Frates James M sold $349,821 worth of shares (10,810 units at $32.36), decreasing direct ownership by 4% to 233,625 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Bedrosian Camille L sold $324,868 worth of shares (10,028 units at $32.40), decreasing direct ownership by 3% to 278,064 units (SEC Form 4) to satisfy tax liability
- SEC Form 144 filed by Amylyx Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank